企業プロフィール
Harmony Biosciences 株価・ニュース・カタリスト
- ティッカー:
- HRMY
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
38.14 USD (+0.05%)
終値
最終更新: 2026年8月17日
1.79B USD
時価総額
株価変動の要因
As of Aug 17, 2026, HRMY was little changed and closed at $38.14. No new same-company headline was identified in the current news window.
企業概要
Sleep and Neurologic Disorders
Harmony Biosciences develops and commercializes medicines for rare neurologic diseases. Its business is anchored by therapies that regulate wakefulness and sleep-wake signaling.
WAKIX Franchise
WAKIX, or pitolisant, is a histamine H3 receptor antagonist/inverse agonist used in narcolepsy and is the company's principal commercial product.
Pitolisant Lifecycle Programs
Harmony is extending pitolisant through a gastro-resistant formulation, a higher-dose program and a newly acquired amorphous form intended to support additional central-nervous-system indications.
Orexin-2 Program
BP-205 is an orexin-2 receptor agonist in Phase 1 development and is intended to complement Harmony's existing wake-promoting franchise with a distinct mechanism.
今後のカタリスト
- NDA submission for a gastro-resistant formulation of pitolisant in the second quarter of 2026.
- Phase 1 pharmacokinetic data for BP-205 around mid-2026.
- Phase 3 data for high-dose pitolisant in 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。